



An Independent Licensee of the Blue Cross Blue Shield Association

EVIDENCE-BASED CRITERIA
SECTION: MEDICINE

ORIGINAL EFFECTIVE DATE: 09/19/22
LAST REVIEW DATE: 12/06/22
CURRENT EFFECTIVE DATE: 12/06/22
LAST CRITERIA REVISION DATE: 12/06/22
ARCHIVE DATE:

NEXT ANNUAL REVIEW DATE: 4TH QTR 2023

QUANTITATIVE ELECTROENCEPHALOGRAPHY AS A DIAGNOSTIC AID FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Evidence-Based Criteria must be read in its entirety to determine coverage eligibility, if any.

This Evidence-Based Criteria provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as "**Description**" defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as "**Criteria**" defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Evidence-Based Criteria are subject to change as new information becomes available.

For purposes of this Evidence-Based Criteria, the terms "experimental" and "investigational" are considered to be interchangeable.

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

EVIDENCE-BASED CRITERIA
SECTION: MEDICINE

ORIGINAL EFFECTIVE DATE: 09/19/22
LAST REVIEW DATE: 12/06/22
CURRENT EFFECTIVE DATE: 12/06/22
LAST CRITERIA REVISION DATE: 12/06/22
ARCHIVE DATE:

NEXT ANNUAL REVIEW DATE: 4TH QTR 2023

QUANTITATIVE ELECTROENCEPHALOGRAPHY AS A DIAGNOSTIC AID FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (cont.)

Description:

Individuals with attention-deficit/hyperactivity disorder (ADHD) may have alterations in their brain wave patterns that can be measured by quantitative electroencephalography (EEG). A commercially available system, the Neuropsychiatric EEG based ADHD Assessment Aid (NEBA®), measures the resting theta/beta ratio of the EEG. This technology is being evaluated to aid in the diagnosis of ADHD in adolescents and children for whom there is a clinical suspicion of ADHD.

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is common in children, adolescents, and adults, and is defined by pervasive symptoms of inattention and/or hyperactivity-impulsivity, which lead to impairment in at least 2 domains of the work, school, or home environments. Stimulant medications reduce symptoms associated with ADHD, although there are concerns about the potential for overdiagnosis and overprescribing of medication.

Criteria:

- Quantitative electroencephalographic-based assessment of the theta/beta ratio as a diagnostic aid for attention-deficit/hyperactivity disorder is considered **experimental or investigational** when any **ONE** or more of the following criteria are met:
 1. Lack of final approval from the appropriate governmental regulatory bodies (e.g., Food and Drug Administration); or
 2. Insufficient scientific evidence to permit conclusions concerning the effect on health outcomes; or
 3. Insufficient evidence to support improvement of the net health outcome; or
 4. Insufficient evidence to support improvement of the net health outcome as much as, or more than, established alternatives, or
 5. Insufficient evidence to support improvement outside the investigational setting

Resources:

Literature reviewed 12/06/22. We do not include marketing materials, poster boards and non-published literature in our review.

1. Adamou M, Fullen T, Jones SL. EEG for Diagnosis of Adult ADHD: A Systematic Review With Narrative Analysis. *Front Psychiatry*. 2020;11:871. doi:10.3389/fpsy.2020.00871
2. Food and Drug Administration. De novo classification request for Neuropsychiatric EEG-Based Assessment Aid for ADHD (NEBA) System (K112711). 2013. Accessed September 3, 2021. https://www.accessdata.fda.gov/cdrh_docs/reviews/K112711.pdf



An Independent Licensee of the Blue Cross Blue Shield Association

EVIDENCE-BASED CRITERIA
SECTION: MEDICINE

ORIGINAL EFFECTIVE DATE: 09/19/22
LAST REVIEW DATE: 12/06/22
CURRENT EFFECTIVE DATE: 12/06/22
LAST CRITERIA REVISION DATE: 12/06/22
ARCHIVE DATE:

NEXT ANNUAL REVIEW DATE: 4TH QTR 2023

QUANTITATIVE ELECTROENCEPHALOGRAPHY AS A DIAGNOSTIC AID FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (cont.)

Resources: (cont.)

3. Gloss D, Varma JK, Pringsheim T, Nuwer MR. Practice advisory: The utility of EEG theta/beta power ratio in ADHD diagnosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology*. Nov 29 2016;87(22):2375-2379. doi:10.1212/WNL.0000000000003265
4. Quantitative Electroencephalography as a Diagnostic Aid for Attention-Deficit/Hyperactivity Disorder TEC Assessments. 2014;Vol. 29:Tab 1. Located at: Blue Cross Blue Shield Association Technology Evaluation Center (TEC), Chicago, USA.
5. Snyder SM, Quintana H, Sexson SB, Knott P, Haque AF, Reynolds DA. Blinded, multi-center validation of EEG and rating scales in identifying ADHD within a clinical sample. *Psychiatry Res*. Jun 30 2008;159(3):346-58. doi:10.1016/j.psychres.2007.05.006
6. Snyder SM, Rugino TA, Hornig M, Stein MA. Integration of an EEG biomarker with a clinician's ADHD evaluation. *Brain Behav*. Apr 2015;5(4):e00330. doi:10.1002/brb3.330
7. van Dijk H, deBeus R, Kerson C, et al. Different Spectral Analysis Methods for the Theta/Beta Ratio Calculate Different Ratios But Do Not Distinguish ADHD from Controls. *Appl Psychophysiol Biofeedback*. Sep 2020;45(3):165-173. doi:10.1007/s10484-020-09471-2
8. Wolraich ML, Hagan JF, Jr., Allan C, et al. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. *Pediatrics*. Oct 2019;144(4)doi:10.1542/peds.2019-2528

Coding:

CPT: 95812, 95813, 95816, 95819, 95957

History:

Medical Policy Panel
Medical Policy Panel

Date:

12/06/22
08/16/22

Activity:

Review with revisions
Approved guideline (Effective 09/19/22)



An Independent Licensee of the Blue Cross Blue Shield Association

**EVIDENCE-BASED CRITERIA
SECTION: MEDICINE**

**ORIGINAL EFFECTIVE DATE: 09/19/22
LAST REVIEW DATE: 12/06/22
CURRENT EFFECTIVE DATE: 12/06/22
LAST CRITERIA REVISION DATE: 12/06/22
ARCHIVE DATE:**

NEXT ANNUAL REVIEW DATE: 4TH QTR 2023

QUANTITATIVE ELECTROENCEPHALOGRAPHY AS A DIAGNOSTIC AID FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (cont.)

Policy Revisions:

12/06/22	Added:	“Insufficient evidence to support improvement of the net health outcome; or”, and “Insufficient evidence to support improvement of the net health outcome as much as, or more than, established alternatives, or” to experimental or investigational criteria section.
12/06/22	Revised:	“Insufficient evidence to support improvement outside the investigational setting” from #3 to #5 in experimental or investigational criteria section.



An Independent Licensee of the Blue Cross Blue Shield Association

EVIDENCE-BASED CRITERIA
SECTION: MEDICINE

ORIGINAL EFFECTIVE DATE: 09/19/22
LAST REVIEW DATE: 12/06/22
CURRENT EFFECTIVE DATE: 12/06/22
LAST CRITERIA REVISION DATE: 12/06/22
ARCHIVE DATE:

NEXT ANNUAL REVIEW DATE: 4TH QTR 2023

QUANTITATIVE ELECTROENCEPHALOGRAPHY AS A DIAGNOSTIC AID FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (cont.)

Non-Discrimination Statement:

Blue Cross Blue Shield of Arizona (BCBSAZ) complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability or sex. BCBSAZ provides appropriate free aids and services, such as qualified interpreters and written information in other formats, to people with disabilities to communicate effectively with us. BCBSAZ also provides free language services to people whose primary language is not English, such as qualified interpreters and information written in other languages. If you need these services, call (602) 864-4884 for Spanish and (877) 475-4799 for all other languages and other aids and services.

If you believe that BCBSAZ has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability or sex, you can file a grievance with: BCBSAZ's Civil Rights Coordinator, Attn: Civil Rights Coordinator, Blue Cross Blue Shield of Arizona, P.O. Box 13466, Phoenix, AZ 85002-3466, (602) 864-2288, TTY/TDD (602) 864-4823, crc@azblue.com. You can file a grievance in person or by mail or email. If you need help filing a grievance BCBSAZ's Civil Rights Coordinator is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at: U.S. Department of Health and Human Services, 200 Independence Avenue SW., Room 509F, HHH Building, Washington, DC 20201, 1-800-368-1019, 800-537-7697 (TDD). Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>

Multi-Language Interpreter Services:

Spanish: Si usted, o alguien a quien usted está ayudando, tiene preguntas acerca de Blue Cross Blue Shield of Arizona, tiene derecho a obtener ayuda e información en su idioma sin costo alguno. Para hablar con un intérprete, llame al 602-864-4884.

Navajo: Díí kwe'é atah nilínigíí Blue Cross Blue Shield of Arizona haada yit'éego bina'idííkidgo éí doodago Háida bíjá anilyeedígíí t'áadoo le'é yína'idííkidgo beehaz'áanii hólo díí t'áa hazaadk'ehjí háká a'doowolgo bee haz'á doo baqah ilínigóó. Ata' halne'ígíí kojí' bich'í' hodíilnih 877-475-4799.

Chinese: 如果您，或是您正在協助的對象，有關於插入項目的名稱 Blue Cross Blue Shield of Arizona 方面的問題，您有權利免費以您的母語得到幫助和訊息。洽詢一位翻譯員，請撥電話 在此插入數字 877-475-4799。

Vietnamese: Nếu quý vị, hay người mà quý vị đang giúp đỡ, có câu hỏi về Blue Cross Blue Shield of Arizona quý vị sẽ có quyền được giúp và có thêm thông tin bằng ngôn ngữ của mình miễn phí. Để nói chuyện với một thông dịch viên, xin gọi 877-475-4799.

Arabic:

إن كان لديك أو لدى شخص تساعد أسئلة بخصوص Blue Cross Blue Shield of Arizona، فلديك الحق في الحصول على المساعدة والمعلومات الضرورية بلغتك من دون أية تكلفة. للتحدث مع مترجم اتصل بـ 877-475-4799.



An Independent Licensee of the Blue Cross Blue Shield Association

**EVIDENCE-BASED CRITERIA
SECTION: MEDICINE**

ORIGINAL EFFECTIVE DATE: 09/19/22
LAST REVIEW DATE: 12/06/22
CURRENT EFFECTIVE DATE: 12/06/22
LAST CRITERIA REVISION DATE: 12/06/22
ARCHIVE DATE:

NEXT ANNUAL REVIEW DATE: 4TH QTR 2023

QUANTITATIVE ELECTROENCEPHALOGRAPHY AS A DIAGNOSTIC AID FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (cont.)

Multi-Language Interpreter Services: (cont.)

Tagalog: Kung ikaw, o ang iyong tinutulungan, ay may mga katanungan tungkol sa Blue Cross Blue Shield of Arizona, may karapatan ka na makakuha ng tulong at impormasyon sa iyong wika ng walang gastos. Upang makausap ang isang tagasalin, tumawag sa 877-475-4799.

Korean: 만약 귀하 또는 귀하가 돕고 있는 어떤 사람이 Blue Cross Blue Shield of Arizona 에 관해서 질문이 있다면 귀하는 그러한 도움과 정보를 귀하의 언어로 비용 부담없이 얻을 수 있는 권리가 있습니다. 그렇게 통역사와 얘기하기 위해서는 877-475-4799 로 전화하십시오.

French: Si vous, ou quelqu'un que vous êtes en train d'aider, a des questions à propos de Blue Cross Blue Shield of Arizona, vous avez le droit d'obtenir de l'aide et l'information dans votre langue à aucun coût. Pour parler à un interprète, appelez 877-475-4799.

German: Falls Sie oder jemand, dem Sie helfen, Fragen zum Blue Cross Blue Shield of Arizona haben, haben Sie das Recht, kostenlose Hilfe und Informationen in Ihrer Sprache zu erhalten. Um mit einem Dolmetscher zu sprechen, rufen Sie bitte die Nummer 877-475-4799 an.

Russian: Если у вас или лица, которому вы помогаете, имеются вопросы по поводу Blue Cross Blue Shield of Arizona, то вы имеете право на бесплатное получение помощи и информации на вашем языке. Для разговора с переводчиком позвоните по телефону 877-475-4799.

Japanese: ご本人様、またはお客様の身の回りの方でも、Blue Cross Blue Shield of Arizona についてご質問がございましたら、ご希望の言語でサポートを受けたり、情報を入手したりすることができます。料金はかかりません。通訳とお話される場合、877-475-4799 までお電話ください。

Farsi:

اگر شما، یا کسی که شما به او کمک میکنید، سوال در مورد Blue Cross Blue Shield of Arizona، داشته باشید حق این را دارید که کمک و اطلاعات به زبان خود را به طور رایگان دریافت نمایید 877-475-4799 [تماس حاصل نمایید.]

Assyrian:

Blue Cross Blue Shield of Arizona، imate prawo da
877-475-4799.

Serbo-Croatian: Ukoliko Vi ili neko kome Vi pomažete ima pitanje o Blue Cross Blue Shield of Arizona, imate pravo da besplatno dobijete pomoć i informacije na Vašem jeziku. Da biste razgovarali sa prevodiocem, nazovite 877-475-4799.

Thai: หากคุณ หรือคนที่คุณกำลังช่วยเหลือตามเกณฑ์ของ Blue Cross Blue Shield of Arizona คุณมีสิทธิที่จะได้รับความช่วยเหลือและข้อมูลในภาษา ของคุณได้โดยไม่มีค่าใช้จ่าย โปรดขยงถาม โทร 877-475-4799